Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $10.00 Average Price Target from Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.00.

A number of equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Finally, Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th.

Autolus Therapeutics Stock Up 4.6%

Shares of AUTL opened at $2.03 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. Autolus Therapeutics has a one year low of $1.18 and a one year high of $2.58. The stock has a market capitalization of $540.30 million, a price-to-earnings ratio of -1.92 and a beta of 2.10. The stock has a 50 day moving average price of $1.97 and a 200 day moving average price of $1.69.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.The company had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Equities research analysts forecast that Autolus Therapeutics will post -0.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after purchasing an additional 8,309 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in shares of Autolus Therapeutics by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after purchasing an additional 11,197 shares during the last quarter. R Squared Ltd raised its holdings in Autolus Therapeutics by 48.4% in the 1st quarter. R Squared Ltd now owns 39,575 shares of the company’s stock valued at $55,000 after buying an additional 12,915 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Autolus Therapeutics by 55.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 44,053 shares of the company’s stock valued at $88,000 after buying an additional 15,647 shares during the period. Finally, Waverly Advisors LLC acquired a new position in Autolus Therapeutics in the first quarter valued at about $37,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc (NASDAQ: AUTL) is a biopharmaceutical company developing and commercializing programmed T-cell therapies for cancer and other serious diseases. The company uses genetic engineering to create CAR T-cell products designed to recognize and eliminate cancer cells while improving control, persistence and safety compared with earlier-generation cell therapies.

Autolus’ lead product, obecabtagene autoleucel, also known as obe-cel and marketed in the United States as AUCATZYL, is a CD19-directed autologous CAR T-cell therapy.